Suchergebnisse - "Oh, Do-Youn"

PubPharm (697)

1

Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor : Pooled Safety Analysis of 469 Patients

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Meric-Bernstam, F. | Hollebecque, A. | Furuse, J. | +7

2

A Phase 1 Study of KIN-3248, an irreversible small molecule pan-FGFR inhibitor, in Patients with Advanced FGFR 2/3 Driven Solid Tumors

enthalten in: Cancer research communications | 2024

von Garmezy, B. | Borad, M. | Bahleda, R. | +8

3

Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)

enthalten in: Journal of clinical pharmacology | 2024

von Garralda, E. | Oh, D. | Italiano, A. | +16

4

Clinical practice guidelines for esophagogastric junction cancer : Upper GI Oncology Summit 2023

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2024

von Kitagawa, Y. | Matsuda, S. | Gotoda, T. | +60

5

Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

enthalten in: Gastric cancer | 2024

von Kitagawa, Y. | Matsuda, S. | Gotoda, T. | +60

6

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585) : an interim analysis of the multicentre, double-blind, randomised phase 3 study

enthalten in: The Lancet. Oncology | 2024

von Shitara, K. | Rha, S. | Wyrwicz, L. | +22

7

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors : Primary Results From the DESTINY-PanTumor02 Phase II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Meric-Bernstam, F. | Makker, V. | Oaknin, A. | +15

CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF10. - PMID 37888905

8

Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103)

enthalten in: The Journal of Clinical Pharmacology | 2024

von Garralda, E. | Oh, D. | Italiano, A. | +16

9

Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019) : A Phase II Basket Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Nakamura, Y. | Mizuno, N. | Sunakawa, Y. | +25

10

Plain language summary of the TOPAZ-1 study : durvalumab and chemotherapy for advanced biliary tract cancer

enthalten in: Future oncology (London, England) | 2023

von Oh, D. | He, A. | Qin, S. | +26

ErratumIn: Future Oncol. 2023 Dec 21;:. - PMID 38126178

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[70]